High BCR-ABL/GUSIS Levels at Diagnosis Are Associated with Unfavorable Responses to Standard Dose Imatinib
Background The approval of second-generation tyrosine kinase inhibitors (TKIs) for the first
line treatment of Chronic Myeloid Leukemia (CML) has generated a need for early molecular …
line treatment of Chronic Myeloid Leukemia (CML) has generated a need for early molecular …
[HTML][HTML] High BCR-ABL/GUSIS levels at diagnosis are associated with unfavorable responses to imatinib
The approval of three tyrosine kinase inhibitors (TKIs) for the first line treatment of Chronic
Myeloid Leukemia (CML) has generated an urgent need for molecular parameters predictive …
Myeloid Leukemia (CML) has generated an urgent need for molecular parameters predictive …
High BCR–ABL/GUSIS Levels at Diagnosis of Chronic Phase CML Are Associated with Unfavorable Responses to Standard-Dose Imatinib
Purpose: The approval of second-generation tyrosine kinase inhibitors (TKIs) for the first-line
treatment of chronic myeloid leukemia (CML) has generated an unmet need for baseline …
treatment of chronic myeloid leukemia (CML) has generated an unmet need for baseline …
[HTML][HTML] High BCR-ABL Levels At Diagnosis Are Associated with Unfavorable Responses to Imatinib Mesylate.
Abstract 2790 The approval of second-generation tyrosine kinase inhibitors (TKIs) for the
first line treatment of Chronic Myeloid Leukemia (CML) has generated a need for early …
first line treatment of Chronic Myeloid Leukemia (CML) has generated a need for early …
[HTML][HTML] The BCR-ABL transcript levels at 3 and 6 months predict the long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib mesylate: a …
F Castagnetti, G Gugliotta, M Breccia, G Specchia… - Blood, 2012 - Elsevier
Abstract Abstract 1678 Background. Imatinib mesylate (IM) is the therapeutic standard for
chronic myeloid leukemia (CML), but nilotinib and dasatinib, at least in selected patients …
chronic myeloid leukemia (CML), but nilotinib and dasatinib, at least in selected patients …
Optimizing early prediction of outcome in CML using the exact decline of BCR-ABL transcript levels within 3 months of imatinib treatment as a prognostic marker
B Hanfstein, V Shlyakhto, M Lauseker, R Hehlmann… - 2013 - ashpublications.org
Introduction Early assessment of BCR-ABL transcript levels at 3 months allows the
prediction of survival and may serve as a trigger for treatment intensification in CML patients …
prediction of survival and may serve as a trigger for treatment intensification in CML patients …
Is the BCR-ABL/GUSB transcript level at diagnosis an early predictive marker for chronic myeloid leukemia patients treated with imatinib?
S Bonecker, M Magnago, J Kaeda, C Solza… - Revista brasileira de …, 2015 - SciELO Brasil
Recently, several follow-up studies upon which the European Leukemia Net 2013 (ELN)
recommendations were based, pointed to the importance of early clearance of leukemic …
recommendations were based, pointed to the importance of early clearance of leukemic …
Monitoring response to imatinib by quantitative real-time polymerase chain reaction (RQ-PCR) in chronic phase, chronic myeloid leukemia patients in complete …
C Pavlovsky, I Giere, V Lombardi, P Negri… - Journal of Clinical …, 2008 - ascopubs.org
18013 Background: Chronic myeloid leukemia (CML) landscape has radically changed
since treatment with imatinib. As the majority of CML patients (pts) treated with imatinib …
since treatment with imatinib. As the majority of CML patients (pts) treated with imatinib …
Clinical implications of discordant early molecular responses in cml patients treated with imatinib
S Stella, V Zammit, SR Vitale, MS Pennisi… - International Journal of …, 2019 - mdpi.com
A reduction in BCR-ABL1/ABL1IS transcript levels to< 10% after 3 months or< 1% after 6
months of tyrosine kinase inhibitor therapy are associated with superior clinical outcomes in …
months of tyrosine kinase inhibitor therapy are associated with superior clinical outcomes in …
Determining the rise in BCR-ABL RNA that optimally predicts a kinase domain mutation in patients with chronic myeloid leukemia on imatinib
RD Press, SG Willis, J Laudadio… - Blood, The Journal …, 2009 - ashpublications.org
In imatinib-treated chronic myeloid leukemia (CML), secondary drug resistance is often
caused by mutations in the BCR-ABL kinase domain (KD). As alternative therapies are …
caused by mutations in the BCR-ABL kinase domain (KD). As alternative therapies are …